Abstract. The integration of artificial intelligence (AI) in cancer research has significantly advanced radiology, pathology, and multimodal approaches, offering unprecedented capabilities in image ...

AbstractPurpose:. Doxorubicin is the first-line treatment for metastatic soft-tissue sarcomas. Ribociclib, a cyclin-dependent kinase 4/6 intargets the retinoblastoma pathway to induce cell-cycle ...

In the U.S., incidence rates of some cancers have increased in 15- to 49-year-olds with concomitant increases in older age groups, suggesting that changes in risk factor prevalence and/or improvements ...

Abstract. Radiomics, the extraction of quantitative data from images, holds promise for noninvasively characterizing tumor phenotypes. Tools like LIFEx have improved the accessibility, transparency, ...

Single-cell analyses of a spontaneous glioblastoma mouse model and tumor-free subventricular zone tissues from patients identify precancerous cells, arising via an oligodendrocyte progenitor lineage, ...

CAR T-cell therapy can successfully treat chemotherapy-resistant B-cell malignancies but has limited effectiveness against solid tumors. The authors report that a fully human CAR targeting the STn ...

AbstractPurpose:. Death receptor (DR)–targeted therapies offer a promising tumor cell–specific therapeutic strategy for highly malignant brain tumors, such as glioblastoma (GBM). However, whether ...

RAS inhibitors have shown early evidence of efficacy in multiple cancer types, but clinical benefit is limited by acquired resistance. Development of best-in-class inhibitors, with optimal potency, ...

Antibody–drug conjugates are an emerging treatment of non–small cell lung cancer. Some do not require biomarkers, whereas others require mutations and/or protein expression. New diagnostic ...

An Iranian missile hit the campus of Israel’s Weizmann Institute of Science, destroying many cancer research labs. Researchers mourned the loss of expensive equipment and irreplaceable samples and ...

The Phase 2 study is evaluating the safety, tolerability, PK, and efficacy of SR-8541A administered orally in combination with botensilimab and balstilimab in patients with refractory metastatic ...

Abstract. Background: KRAS mutations are the most frequently encountered driver oncogene, involved in ~25% of all human cancers [1,2]. KRASG12D is the predominant KRAS mutation isoform, detected in ...